Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 12,236 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Sarcoma, Adenocarcinoma, Carcinoma, Multiple Myeloma, Desmoplastic Small Round Cell Tumor
Interventions: Ascorbic acid (vitamin C); Drug
Lead sponsor: Situs Cancer Research Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: TSC
Interventions: JASPER; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Months to 36 Months
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke, Patent Foramen Ovale, PFO
Interventions: Investigational PFO Closure Device, Standard of Care PFO Closure Device; Device
Lead sponsor: Occlutech International AB; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Stanford, California • Thousand Oaks, California + 20 more

Conditions: Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer
Interventions: PCA062; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Childhood Obesity
Interventions: Bottle Weaning Intervention; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 12 Months to 13 Months
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Postherpetic Neuralgia
Interventions: ATx08-001, Placebo; Drug
Lead sponsor: Aestus Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 9
States / cities: Chandler, Arizona • Peoria, Arizona • Cutler Bay (Miami), Florida + 5 more

Conditions: Arthritis
Interventions: Birmingham Hip Resurfacing; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2025
U.S. locations: 7
States / cities: Tucson, Arizona • Lake Charles, Louisiana • New York, New York + 4 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Buffalo, New York • Cleveland, Ohio + 1 more

Conditions: Suicide, Alcohol Use Disorder
Interventions: Qungasvik (Tools for Life); Behavioral
Lead sponsor: University of Alaska Fairbanks; Other
Eligibility: 12 Years to 21 Years
Enrollment: 542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Fairbanks, Alaska

Conditions: Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions: Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Fludarabine, Rituximab; Radiation · Procedure · Biological + 1 more
Lead sponsor: Noah Merin; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Meningococcal Meningitis
Interventions: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 37 Months to 63 Months
Enrollment: 433 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • Downey, California • Oakland, California + 15 more

Conditions: Diabetes, Hypertension, Dyslipidemia
Interventions: MEDIC; Other
Lead sponsor: Providence VA Medical Center; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: COVID-19
Interventions: Placebo for SLV213, SLV213; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Arthritis, Psoriatic
Interventions: Placebo matching BMS-945429, BMS-945429; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more

Conditions: Renal Cell Carcinoma
Interventions: ASONEP; Drug
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Duarte, California • Fort Myers, Florida • Inverness, Florida + 2 more

Conditions: Plasma Cell Myeloma
Interventions: Belantamab Mafodotin, Lenalidomide; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Huntsville, Alabama • Huntington Beach, California • Santa Maria, California + 27 more

Conditions: Fabry Disease
Interventions: PRX-102 1 mg/kg every two weeks; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 6
States / cities: Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Lu AG13909; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: TmPSMA-02; Biological
Lead sponsor: Tceleron Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia
Interventions: ASP4345, Matching Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Relugolix; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 96
States / cities: Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more

Search by objective public record fields.

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

TSC Remote Assessment and Intervention

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

PCA062 in pCAD-positive Tumors.

Feeding Young Children Study: Bottle Weaning Intervention

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

A Safety and Efficacy Study of the Birmingham Hip Resurfacing System

Avonex 15 Year Long Term Follow-up Study

Qungasvik (Toolbox): Prevention of Alcohol/Suicide Risk in Alaska Native Youth

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes

Safety Study of SLV213 for the Treatment of COVID-19.

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX